Bone Biologics Corporation
BBLG · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.00 | 0.11 | 0.03 |
| FCF Yield | -11.81% | -20.41% | -6.06% | -8.12% |
| EV / EBITDA | -21.44 | 5.87 | -12.32 | -8.76 |
| Quality | ||||
| ROIC | -11.89% | -11.34% | -35.68% | -44.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.62 | 0.91 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -28.88% | 50.45% | 31.58% | -136.56% |
| Safety | ||||
| Net Debt / EBITDA | -124.63 | 8.88 | 2.70 | 2.19 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |